Additionally, a European re-evaluation of tofacitinib was carried out in May 2019 following the interim analyses of clinical study A3921133 that demonstrated an increased risk of severe venous thromboembolism compared to tumor necrosis factor inhibitors at a dosage of 10 mg twice daily [22]. The gene discussed is TNF; the disease is venous thromboembolism.